Pluristem Therapeutics has moved its operations into an advanced GMP facility near Matam Park in Haifa, Israel.
Factory in a box products include vaccines, oncolytic viruses, and gene and cell therapies.
The project has now shared protein data for more than 80% of the human protein-coding genes and RNA expression data for more than 90% of the genes.
Product uses heat-inactivation technology and preserves components in their in vivo state.
Agreement covers nine immunoassays, six chemistry systems, and three automation lines.
Bayer is ponying up over €500 million to set up capacities for the manufacturing of recombinant factor VIII (rFVIII) hemophilia products.
Joint fund will back research over 10 years, with initial projects getting $3.5 million.
The group plans to develop a plasmid vaccine to generate viral protein that will become an antigen.
Please wait while you are redirected to the right page...